OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Martin on Autologous Stem Cell Transplant in Multiple Myeloma

October 12th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses autologous stem cell transplant (ASCT) in multiple myeloma.

Dr. Borghaei on Molecular Profiling in Lung Cancer

October 12th 2018

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses molecular profiling in lung cancer.

Dr. Radich on Compliance to NCCN Guidelines in CML

October 12th 2018

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses compliance to the NCCN guidelines in the treatment of patients with chronic myeloid leukemia (CML).

Dr. O'Donnell Compares Checkpoint Inhibitors in Bladder Cancer

October 12th 2018

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, compares checkpoint inhibitors in the treatment of patients with bladder cancer.

Dr. Sweis on Sequencing of Therapies in Prostate Cancer

October 12th 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the sequencing of therapies in prostate cancer.

Dr. Melisko Reflects on Findings From the MINDACT Trial in Breast Cancer

October 11th 2018

Michelle E. Melisko, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, reflects on the findings from the MINDACT trial in breast cancer.

Dr. Ginsburg Discusses the Use of VIA in Cervical Cancer Screening

October 11th 2018

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses the use of visual inspection with acidic acid (VIA) in cervical cancer screening.

Dr. Flaherty Discusses BRAF Inhibitors in Melanoma

October 11th 2018

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses BRAF inhibitors for the treatment of patients with melanoma.

Dr. Forster on Next Steps With Lurbinectedin in SCLC

October 11th 2018

Martin Forster, MD, a medical oncologist, University College London Hospitals, discusses the next steps with the investigational agent lurbinectedin in combination with doxorubicin as a second-line therapy for patients with small cell lung cancer (SCLC).

Dr. Papadimitrakopoulou on Biomarker-Driven Clinical Trials in NSCLC

October 11th 2018

Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses biomarker-driven clinical trials in non–small cell lung cancer.

Dr. Zarour on Unmet Needs in Melanoma

October 10th 2018

Hassane M. Zarour, MD, professor of medicine, University of Pittsburgh, discusses unmet needs in melanoma.

Dr. Garon Discusses Driver Mutations in SCLC

October 10th 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses driver mutations in small cell lung cancer.

Dr. Arora Discusses the Role of MRD Status in CLL

October 10th 2018

Shagun Arora, MD, assistant clinical professor at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of minimal residual disease (MRD) status in the treatment of patients with chronic lymphocytic leukemia.

Dr. Verstovsek on Accelerated Phase Myelofibrosis

October 10th 2018

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses accelerated phase myelofibrosis.

Dr. Hurvitz on Novel Agents in HER2-Positive Breast Cancer

October 10th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses novel agents in HER2-positive breast cancer.

Dr. Tasian on Genetic Testing in Pediatric ALL

October 10th 2018

Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses genetic testing in pediatric acute lymphoblastic leukemia.

Dr. McCollum on Maintenance Therapy for Metastatic CRC

October 10th 2018

A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses maintenance therapy for patients with metastatic colorectal cancer.

Dr. Daskivich Discusses Active Surveillance in Prostate Cancer

October 10th 2018

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses active surveillance for patients with prostate cancer.

Dr. Whitman on Improving Precision Medicine in Oncology

October 10th 2018

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses improving precision medicine in oncology.

Dr. Wong on a Trial With an Anti-CD46 Antibody in Myeloma

October 10th 2018

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses a trial with an anti-CD46 antibody in multiple myeloma.